Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding
Navidea Biopharmaceuticals, Inc. (NAVB)
NASDAQ:AMEX Investor Relations:
ir.navidea.com
Company Research
Source: Business Wire
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreements with two existing investors, including John K. Scott, Jr. (collectively, the “Investors”), to purchase approximately 4.0 million shares of the Company’s common stock, par value $0.001 per share, for aggregate gross proceeds to Navidea of approximately $3.4 million. The securities to be issued to the Investors will represent approximately 16.5% of the Company’s outstanding common stock after such issuance.In addition, the Company executed a binding term sheet to sell the judgment entered by the Ohio Court of Common Pleas in favor of Navidea in the amount of $4.3 million plus interest (the “Judgment”), for $4.2 million of proceeds to Navidea. The Company has the option, within 45 days of the sale, to repurchase the Judgmen
Show less
Read more
Impact Snapshot
Event Time:
NAVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAVB alerts
High impacting Navidea Biopharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NAVB
News
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat